ARCHIVES

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

This article is from The Cancer Letter archive.

Vol. 25 No. 6 | June 28, 2002

Download PDF Visit The Full Archive

Related Articles

NCI Boosts Funding For Cooperative Groups by $25 Million, Cuts Overall Accrual by 20 Percent, to 20,000 Patients

November 11, 2011

No More Free Cancergrams, But NCI Will Save a Bundle

October 17, 1986

CAP Issues Active Surveillance Guidance For Prostate Cancer

September 5, 2014

Extramural Advisory Board Members Listed

October 20, 1995

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

Fox Chase Joins Plan For Free Cancer Screening

May 9, 1986